CG Oncology, Inc. Operating Cash Flow
CG Oncology, Inc. (CGON) reported Operating Cash Flow of -$103.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-06
- CG Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$46.41M.
- CG Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$56.94M.
- CG Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$36.22M.
- CG Oncology, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$38.89M.
- CG Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$132.35M.
- CG Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2024 was -$78.71M.
- CG Oncology, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$45.68M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$46.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$103.36M 10-Q · filed 2026-08-06 | -$139.57M derived: sum of 3 quarters · filed 2026-08-06 | -$178.47M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$56.94M 10-Q · filed 2026-05-08 | -$93.16M derived: sum of 2 quarters · filed 2026-05-08 | -$132.05M derived: sum of 3 quarters · filed 2026-05-08 | -$160.01M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$36.22M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$75.11M derived: sum of 2 quarters · filed 2026-02-27 | -$103.07M derived: sum of 3 quarters · filed 2026-08-06 | -$132.35M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$38.89M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$66.85M derived: sum of 2 quarters · filed 2026-08-06 | -$96.13M 10-Q · filed 2025-11-14 | -$116.79M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$27.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$57.24M 10-Q · filed 2026-08-06 | -$77.90M derived: sum of 3 quarters · filed 2026-08-06 | -$93.82M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$29.28M 10-Q · filed 2026-05-08 | -$49.94M derived: sum of 2 quarters · filed 2026-05-08 | -$65.86M derived: sum of 3 quarters · filed 2026-05-08 | -$81.98M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | -$20.66M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$36.58M derived: sum of 2 quarters · filed 2026-02-27 | -$52.70M derived: sum of 3 quarters · filed 2026-02-27 | -$78.71M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$15.92M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$32.04M derived: sum of 2 quarters · filed 2025-11-14 | -$58.05M 10-Q · filed 2025-11-14 | -$72.70M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$16.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-08 | -$42.13M 10-Q · filed 2025-08-08 | -$56.78M derived: sum of 3 quarters · filed 2026-02-27 | -$69.04M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$26.01M 10-Q · filed 2025-05-13 | -$40.66M derived: sum of 2 quarters · filed 2026-02-27 | -$52.92M derived: sum of 3 quarters · filed 2026-02-27 | -$63.70M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$14.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$26.91M derived: sum of 2 quarters · filed 2026-02-27 | -$37.69M derived: sum of 3 quarters · filed 2026-02-27 | -$45.68M 10-K · filed 2026-02-27 |
| 2023-09-30 | -$12.26M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$23.05M derived: sum of 2 quarters · filed 2024-11-12 | -$31.03M 10-Q · filed 2024-11-12 | |
| 2023-06-30 | -$10.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$18.77M 10-Q · filed 2024-08-08 | ||
| 2023-03-31 | -$7.99M 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |